erlotinib hydrochloride has been researched along with efatutazone in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (efatutazone) | Trials (efatutazone) | Recent Studies (post-2010) (efatutazone) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 25 | 4 | 17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koh, Y; Murakami, H; Serizawa, M; Takahashi, T; Watanabe, M; Yamamoto, N | 1 |
1 other study(ies) available for erlotinib hydrochloride and efatutazone
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Smad2 Protein; Thiazolidinediones; Transforming Growth Factor beta2; Wound Healing | 2014 |